Anti- Human HLA-B27 (HLA-ABC-m3)

The monoclonal antibody Anti-HLA-B27 is directed against the HLA-B27 antigen, a class I surface molecule encoded by the B locus of the human Major Histocompatibility Complex (MHC). This antigen plays a key role in the presentation of microbial peptides to T cells, contributing to immune recognition and response 1.

HLA-B27 is expressed in approximately 7% of the Caucasian population, while a related antigen, HLA-B7, is found in about 22%2. The detection of HLA-B27 is clinically significant due to its strong association with inflammatory diseases, particularly ankylosing spondylitis. Over 90% of individuals diagnosed with ankylosing spondylitis express the HLA-B27 antigen, compared to only 7% of asymptomatic individuals3. This monoclonal antibody enables the identification of HLA-B27 specificity within the class I HLA allotype, supporting the diagnosis and monitoring of spondyloarthropathies. Flow cytometry using CYT HLAIB27F provides a rapid and reliable method for assessing HLA-B27 expression in clinical samples 3.

Furthermore, structural and functional studies have shown that HLA-B27 may contribute to disease pathogenesis through mechanisms involving misfolding, aberrant immune responses, and interactions with innate immune receptors.